TP53

Overview

TP53 (tumor protein p53) is one of the most studied and clinically significant tumor suppressor genes in human biology. The protein it encodes, p53, functions as a sequence-specific transcription factor that orchestrates cellular responses to genotoxic stress, oncogenic signaling, and metabolic disruption. Upon activation, p53 transcriptionally regulates a broad network of downstream effectors governing cell cycle arrest, apoptosis, DNA repair, and senescence. Canonical p53 targets include the cyclin-dependent kinase inhibitor p21 (CDKN1A), the pro-apoptotic proteins Bax and BBC3 (PUMA), and anti-proliferative regulators such as p16, all of which mediate context-dependent cellular outcomes. The protein is subject to extensive post-translational regulation, including phosphorylation, acetylation, and ubiquitin-mediated degradation via MDM2, the primary negative regulator of p53 stability.

Mutations in TP53 occur in more than half of all human malignancies, making it the most frequently altered gene in cancer. These mutations are broadly classified as loss-of-function, dominant-negative, or gain-of-function variants, many of which cause protein misfolding and abrogation of wild-type transcriptional activity. Beyond somatic mutations, germline TP53 mutations underlie Li-Fraumeni syndrome (LFS), a hereditary cancer predisposition disorder associated with markedly elevated lifetime cancer risk. The extraordinary breadth of p53's biological roles—spanning tumor suppression, inflammatory regulation, metabolic homeostasis, aging, and immunity—has made it a central target in oncology drug discovery and translational research.

Focus of Latest Publications

TP53 mutations emerge as a critical stratification parameter across multiple malignancies, consistently predicting unfavorable outcomes and therapeutic resistance. In acute myeloid leukemia treated with venetoclax and hypomethylating agents, TP53 mutations independently predicted inferior overall survival; stratification by allelic state (single versus multihit mutations) further refined prognosis, with multihit TP53 disease showing median survival of 3.8 months compared to 7.0 months for single-hit cases. In non-muscle-invasive bladder cancer, TP53 alterations characterized a distinct molecular cluster with specific therapeutic vulnerabilities, while in diffuse large B-cell lymphoma, TP53 mutations predominated in endoderm-derived extranodal invasion with worse progression-free and overall survival. Secondary TP53 mutations conferred resistance to BRAF-targeted therapy in anaplastic thyroid cancer cells. These findings underscore TP53 status as a fundamental determinant of disease biology and treatment response across hematologic and solid malignancies.

Therapeutic strategies increasingly target TP53 dysfunction through structure-based drug design and natural product discovery. Small-molecule reactivation of TP53-Y220C, achieved with compounds bearing zinc-chelation and Michael acceptor moieties, induced p53-dependent target gene expression and enhanced chemotherapy response in gastric cancer models. Plant-derived extracts—from Carissa macrocarpa, Artemisia monosperma, and Hypericum lancasteri—upregulated p53 expression and induced apoptosis in colorectal cancer and chronic myeloid leukemia cells through multiple pathways. Novel synthetic anthra[2,3-b]furan derivatives demonstrated submicromolar cytotoxicity comparable to doxorubicin while circumventing p53-mediated multidrug resistance through dual topoisomerase inhibition. Gene delivery vehicles, including multifunctional PEI polymers engineered to co-deliver p53 and ferroptosis-inducing iron sources, achieved synergistic antitumor activity by simultaneously restoring p53-dependent apoptosis and inducing ferroptosis.

Combinatorial approaches leverage TP53-pathway reactivation alongside conventional and emerging modalities. progesterone receptor modulation combined with PARP inhibition synergistically enhanced p53-dependent apoptosis in endometriotic lesions. CAR T cells targeting urokinase plasminogen activator receptor, enriched on senescent stromal cells within TP53- and RAS-mutant solid tumors, induced durable regressions and eliminated systemic metastases. In TP53-mutant AML characterized by ribosomal protein gene deletions, HSP90 inhibition emerged as a selective therapeutic vulnerability. Genome editing via Prime Editing-Microhomology-Enabled Replacement successfully replaced murine Trp53 with human TP53 coding sequence, generating functional humanized mice for complex disease modeling.

TP53 pathway functions extend beyond cancer biology to immune homeostasis and age-related neurodegeneration. PERP, a p53 target gene encoding an apoptosis regulator, proved essential for thymic negative selection; PERP-deficient mice exhibited impaired clonal deletion and age-associated autoimmune arthritis. In hippocampal neuronal aging, histone lactylation of Trp53 and other aging-related genes via TEAD-YAP signaling connected iron homeostasis to p53-dependent transcription. In advanced metastatic prostate cancer, p53 pathway upregulation, identified through plasma extracellular vesicle proteomics, paradoxically associated with worse progression-free and overall survival, underscoring context-dependent roles for p53 signaling in cancer progression.